GlassScriptPhysician profile
Timothy Robert Canan
NPI 1457650038
$15,351.37
in general payments reported to CMS, 2019-2025
22 companies · $735 in 2025
The $735 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,305 · 2020: $1,327 · 2021: $1,761 · 2022: $1,668 · 2023: $2,985 · 2024: $2,570 · 2025: $735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,591 · Travel and Lodging: $699.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,591.23 |
| Travel and Lodging | $698.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $7,330.71 | 2019-2025 | Pressurewire, Coroflow, Dragonfly Opstar |
| Edwards Lifesciences Corporation | $1,597.04 | 2019-2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Philips North America LLC | $1,244.07 | 2019-2024 | (Bq9) Coronary Ivus |
| Abiomed | $1,208.50 | 2019-2025 | Impella |
| Shockwave Medical, INC | $750.30 | 2023-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Medtronic, INC. | $704.73 | 2021-2024 | Corevalve Evolut R, Selectsecure, Linq II |
| Astrazeneca Pharmaceuticals LP | $476.52 | 2021-2023 | Farxiga |
| Chiesi USA, INC. | $410.88 | 2019-2023 | Kengreal |
| Janssen Pharmaceuticals, INC | $218.42 | 2021-2024 | Xarelto |
| Acist Medical Systems, INC. | $180.30 | 2020-2022 | |
| Corindus INC. | $176.63 | 2019 | |
| Terumo Medical Corporation | $152.35 | 2019-2021 | |
| Cardiovascular Systems INC. | $144.53 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $125.11 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.99 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $122.84 | 2019 | |
| Atricure, INC. | $111.49 | 2019 | |
| Pfizer INC. | $102.45 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $86.82 | 2024 | Arcalyst |
| Impulse Dynamics (USA) INC. | $35.97 | 2024 | Optimizer |
| Biotronik INC. | $34.33 | 2021-2024 | Pamira |
| Actelion Pharmaceuticals US, INC. | $14.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Canan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.